Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

نویسندگان

چکیده

Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and sarcoma (MS) has presented challenges for decades. Studies on selinexor in combination with various standard intensive chemotherapy regimens the treatment R/R AML have demonstrated promising results. This study aimed to evaluate efficacy safety chemotherapy-free low-dose MS patients. Methods: Ten patients who received at Tongji Hospital from October 2021 August 2022 were included this study. The primary endpoint was overall response rate (ORR) secondary endpoints complete remission (CR), CR incomplete hematological recovery (CRi), partial (PR), transplantation rate, safety. Results: All evaluable response, achieving four (40.0%) CRi two (20.0%) a total CR/CRi 60.0%. ORR 80.0% when PR included. Five (50.0%) underwent allogeneic hematopoietic stem cell (allo-HSCT) after selinexor-containing regimens. At end follow-up, seven (70.0%) alive, three died transplant-related complications disease progression. most frequently reported nonhematologic adverse events (AEs) grade 1 2 asymptomatic hyponatremia. Conclusion: are feasible tolerable provide an opportunity receive transplantation.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.

CONTEXT Young patients affected by acute myeloid leukemia (AML) achieve complete remission (CR) using conventional chemotherapy in about 55-85%. However, 30% of patients fail to achieve CR and the remission duration is often only about 12 months. More intensive treatment after CR seems to be necessary in order to maintain CR and obtain a definitive cure. In Brazil, few reports have been publish...

متن کامل

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia

The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared 92 and 107 patients treated, respectively, with intensive chemotherapy or azacitidine within two centres. Diagnoses were 37.5% post-myelodysplastic syndrome, 17.4% post-myeloproliferative ...

متن کامل

influence of chemotherapy on the lipid peroxidation and antioxidant status in patients with acute myeloid leukemia

chemotherapeutic agents used in patients with cancer cause to generate the enormous amounts of free radicals associated with cell injury. in this study we assess the effects of chemotherapy regimen on oxidant/antioxidant status in patients with acute myeloid leukemia (aml). 38 newly diagnosed patients with acute myeloid leukemia were recruited in this study. all patients received cytarabine and...

متن کامل

Myeloid Sarcoma in an Eyelid That Developed during Chemotherapy for Acute Myeloid Leukemia.

An 80-year-old female presented with a mass in the left upper eyelid margin that had developed during chemotherapy for acute myeloid leukemia. The mass was elastic, hard, and pinkish, with a relatively smooth surface but without madarosis. The histopathological findings corresponded to a myeloid sarcoma. No blast cells were shown in the peripheral blood at the time of biopsy, and she subsequent...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Frontiers in Pharmacology

سال: 2023

ISSN: ['1663-9812']

DOI: https://doi.org/10.3389/fphar.2023.1217701